BofA/Merrill Lynch Downgrades Eli Lilly (LLY) to Neutral, Upside Priced In
Get Alerts LLY Hot Sheet
Rating Summary:
24 Buy, 8 Hold, 2 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Eli Lilly (NYSE: LLY) from Buy to Neutral with a price target of $74.00 (from $70.00), saying 2015 positives are already priced in.
Analyst Colin Bristow said while they remain constructive on the company and expect solid launches for Trulicity, Jardiance and Cyramza, they believe the current valuation already reflects this. Solanezumab (Alzhimer's) and evacetrapib (CV risk reduction) provided the next leg of upside but there will unlikely be meaningful data in 2015.
For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.
Shares of Eli Lilly closed at $70.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Estee Lauder (EL) to Buy; 'Earnings have bottomed'
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- BofA Securities Downgrades Galapagos NV (GLPG) to Underperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Downgrades, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!